Prellis Biologics
Develops holographic bioprinting technology for creating complex human tissues and lymph node models to enable rapid antibody discovery, reducing lead times from 9 months to 16 days.
- CEO / Founder
- Michael Nohaile
- Team Size
- 11-50
- Stage
- Active
- Total Funding
- $64.5M
- Latest Round
- Series C
- Key Investors
- Avidity Partners, Celesta Capital, Khosla Ventures, True Ventures, Indie Bio (SOSV)
Technology & Products
Key Products
Externalized Immune System (EXIS) platform; Lymph node organoids (LNOs)
Technological Advantage
CLAIMED: Proprietary laser-based holography enables large, complex tissue co-cultures. VERIFIED: Platform demonstrated discovery of 300 SARS-CoV-2 antibodies in 16 days, significantly faster than the 9-month industry standard.
Differentiation
Value Proposition
Reduces antibody discovery cost and time (9 months to 16 days) by utilizing an Externalized Immune System (EXIS) platform that mimics human immune responses without animal testing.
How They Differentiate
Differentiates through high-resolution (10-20 micron) holographic printing vs. traditional bioprinting, specifically optimized for immune system modeling and antibody discovery rather than structural tissue replacement.
Market & Competition
Target Customers
Biotechnology and pharmaceutical industries
Industry Verticals
Biotechnology; Pharmaceuticals
Competitors
Aspect Biosystems (microfluidic bioprinting for therapeutic tissues), Cellink (BICO) (light-based and extrusion bioprinting systems), Organovo (3D bioprinted human tissues for drug discovery and development).
Growth & Milestones
Growth Metrics
Antibody discovery time reduced from 9 months to 16 days; Generated 300 human antibodies binding SARS-CoV-2.
Major Milestones
Founded in October 2016; Generated 300 human antibodies for SARS-CoV-2; Raised $35M Series C funding; Appointed Mike Nohaile as CEO
Notable Customers
Bristol Myers Squibb, Eli Lilly and Company